Korean Drug Co. Ltd (014570) — Cash Flow-to-Debt Ratio
Korean Drug Co. Ltd (014570) has a Cash Flow-to-Debt Ratio of 0.47x as of March 2026, meaning its operating cash flow of ₩6.60 Billion could theoretically repay 0% of its total liabilities (₩14.09 Billion) in one year. Explore Korean Drug Co. Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Korean Drug Co. Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Korean Drug Co. Ltd across 12 annual periods. Also explore Korean Drug Co. Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Korean Drug Co. Ltd (2014–2025)
Year-by-year debt coverage analysis for Korean Drug Co. Ltd. For market capitalisation and broader financial context, see 014570 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.17x | ₩13.11 Billion | ₩11.25 Billion | ▲ +158.1% |
| 2024 | 0.45x | ₩4.87 Billion | ₩10.78 Billion | ▲ +385.1% |
| 2023 | -0.16x | ₩-2.00 Billion | ₩12.62 Billion | ▼ -126.3% |
| 2022 | 0.60x | ₩5.91 Billion | ₩9.80 Billion | ▼ -18.3% |
| 2021 | 0.74x | ₩8.81 Billion | ₩11.92 Billion | ▼ -25.3% |
| 2020 | 0.99x | ₩12.33 Billion | ₩12.47 Billion | ▲ +71.9% |
| 2019 | 0.57x | ₩6.21 Billion | ₩10.80 Billion | ▲ +0.9% |
| 2018 | 0.57x | ₩5.79 Billion | ₩10.16 Billion | ▲ +1150.7% |
| 2017 | 0.05x | ₩447.20 Million | ₩9.82 Billion | ▼ -88.8% |
| 2016 | 0.41x | ₩3.96 Billion | ₩9.75 Billion | ▼ -36.9% |
| 2015 | 0.64x | ₩6.13 Billion | ₩9.52 Billion | ▲ +93.2% |
| 2014 | 0.33x | ₩4.46 Billion | ₩13.38 Billion | — |